Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets analyst projections.
Overview
One multi-cancer early detection (MCED) test company's stock has soared 171% over the last six months, but is up a more modest 64% overall in 2026. The discrepancy in Grail's (NASDAQ: GRAL) stock performance reflects a strong recovery from the tumultuous events of mid-February, when the company announced it had missed the primary endpoint in a landmark trial. The underlying causes behind this volatility are likely to play out in deciding where the company will be over the next half-decade.
Let's start by looking at some numbers, and then get into the key detail: what to believe in the numbers.
Details
As you can see below, Grail isn't profitable or cash-generative yet, and according to Wall Street, it won't be until 2032/2033. That might make the stock look unattractive to many. However, it's worth considering that, under these estimates, revenue will grow at a 30% rate as its MCED test, Galleri, continues to gain adoption by medical insurers, and test sales balloon from 247,000 in 2026 to 832,0000 in 2030.
Source
Originally published at www.fool.com.